Results 221 to 230 of about 2,228,393 (268)
Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma. [PDF]
Future OncolMartin TG +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
on the Side Effects of Butazolidin
Scandinavian Journal of Rheumatology, 1961SummaryNo risk should be involved in the use of butazolidin under hospital conditions when the dosage remains moderate. An average daily dose of 300 mg. is generally sufficient. Care should be taken to give the patients adequate information regarding the dose and the side effects.There are also no risks involved in the clinical use of butazolidin in ...
V A, LAINE, O, PASTINEN
openaire +2 more sources
Clinical and Experimental Hypertension. Part A: Theory and Practice, 1983
Diuretics are amongst the most widely used drugs. Fortunately enough, there are rather few clinically relevant side effects. The following side effects are discussed in this paper: disturbances of electrolyte, acid-base- and water balance, metabolic changes (uric-acid, carbohydrate-metabolism, lipid metabolism), unspecific side effects and drug ...
H, Losse, H, Zumkley, T, Quante
openaire +2 more sources
Diuretics are amongst the most widely used drugs. Fortunately enough, there are rather few clinically relevant side effects. The following side effects are discussed in this paper: disturbances of electrolyte, acid-base- and water balance, metabolic changes (uric-acid, carbohydrate-metabolism, lipid metabolism), unspecific side effects and drug ...
H, Losse, H, Zumkley, T, Quante
openaire +2 more sources
Oncology, 2003
Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis. Mesna administration can control the urothelial toxicity of ifosfamide, but it is without effect on the other complications.
openaire +3 more sources
Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis. Mesna administration can control the urothelial toxicity of ifosfamide, but it is without effect on the other complications.
openaire +3 more sources
Archives of General Psychiatry, 1990
To the Editor.— Bouchard and colleagues1recently reported an increased risk of extrapyramidal signs and symptoms during treatment with fluoxetine or other potent and selective inhibitors of neuronal uptake of serotonin. Others have noted such symptoms when this new antidepressant was combined with a neuroleptic agent,2leading to the question of ...
R J, Baldessarini, E, Marsh
openaire +2 more sources
To the Editor.— Bouchard and colleagues1recently reported an increased risk of extrapyramidal signs and symptoms during treatment with fluoxetine or other potent and selective inhibitors of neuronal uptake of serotonin. Others have noted such symptoms when this new antidepressant was combined with a neuroleptic agent,2leading to the question of ...
R J, Baldessarini, E, Marsh
openaire +2 more sources
Cardiology, 2001
Clopidogrel is a recently developed thrombocyte inhibitor with fewer side effects. We report 2 patients with purpura and thrombopenia, respectively, due to clopidogrel therapy. As this compound is widely used in clinical practice, the occurrence of hematological and dermal side effects should be considered.
F, Reichenberger, H, Wirtz, R, Paschke
openaire +2 more sources
Clopidogrel is a recently developed thrombocyte inhibitor with fewer side effects. We report 2 patients with purpura and thrombopenia, respectively, due to clopidogrel therapy. As this compound is widely used in clinical practice, the occurrence of hematological and dermal side effects should be considered.
F, Reichenberger, H, Wirtz, R, Paschke
openaire +2 more sources
Drug Safety, 1991
Ranitidine was first marketed in 1981; since then many patients have been treated such that much experience has been accumulated on the safety of this histamine H2-receptor antagonist in the treatment of gastroduodenal disease. A wide array of ranitidine-associated side effects has been described, but infrequently.
T, Vial +5 more
openaire +2 more sources
Ranitidine was first marketed in 1981; since then many patients have been treated such that much experience has been accumulated on the safety of this histamine H2-receptor antagonist in the treatment of gastroduodenal disease. A wide array of ranitidine-associated side effects has been described, but infrequently.
T, Vial +5 more
openaire +2 more sources